Taysha Gene Therapies stock has delivered a very strong 231.9% return over the past three years, yet current valuation checks and market multiples point to a less straightforward picture of whether the recent gains leave enough room for upside from here.

• The stock is up 231.9% over three years, which puts extra weight on whether recent optimism about its gene therapy pipeline is already reflected in the share price.
• Progress on TSHA-102 for Rett syndrome, including completed dosing in key trials and expanded commercial manufacturing with Catalent, can support high expectations. However, any setback in clinical data or regulatory feedback may quickly reset those expectations.
• Taysha Gene Therapies scores 3 out of 6 on our valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.

For investors, the debate is whether Taysha Gene Therapies' recent share price strength already prices in the key milestones ahead for TSHA-102 or still leaves a margin of safety.

Does Taysha Gene Therapies Look Pricey on Book Value?

P/B is a useful lens for Taysha Gene Therapies because the company is still loss making, so earnings based multiples such as P/E are less helpful. The stock currently trades on a P/B of 9.8x compared with a Biotechs industry average of about 2.5x. That is a sizeable premium to the sector, even though many peers also carry heavy research and development spending and uncertain paths to profitability.

Despite the recent progress around TSHA-102 and the expanded Catalent manufacturing agreement, this premium indicates that Taysha Gene Therapies already carries a high valuation against its asset base. The model also flags that the gap is extreme. This suggests that this framework is heavily penalising the company’s current losses and risk profile rather than pointing to a precise fair value line.

On P/B, Taysha Gene Therapies stock appears significantly more expensive relative to the wider biotech sector.

The Taysha Gene Therapies Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Taysha Gene Therapies aim to close the gap between today’s mixed valuation signals and the expectations that might sit behind Taysha Gene Therapies' share price, by spelling out what would need to happen to future growth, margins and earnings for the stock to be worth materially more or less than it is today on the Community page. Each narrative ties a fair value to a specific mix of potential catalysts and risks so you can track which storyline comes closest to reality over time.

One of the top community narratives on Taysha Gene Therapies: 65% undervalued

"Breakthrough Therapy designation and full FDA alignment on the pivotal REVEAL trial design and statistical plan provide an expedited, de-risked path to potential BLA submission, which can accelerate the timing of first commercial revenue and pull forward the company’s earnings inflection…"

Do you think there's more to the story for Taysha Gene Therapies? Head over to our Community to see what others are saying!

The Bottom Line

Taysha Gene Therapies now screens as overvalued on traditional market multiples, with an extreme gap against sector peers that reflects heavy current losses and a high perceived risk profile. That does not rule out further upside, but it does mean the valuation already leans heavily on a supportive outcome for TSHA-102 and related milestones. For you as an investor, the key question is whether the clinical and regulatory path for Rett syndrome evolves cleanly enough to sustain that premium, or whether any disappointment forces the multiple to reset closer to the broader biotech group.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.